meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced NSCLC (mNSCLC) - 1st line (L1)
mNSCLC - L1 - all population
5
mNSCLC - L1 - EGFR mutant
mNSCLC - L1 - PDL1 negative
1
mNSCLC - L1 - PDL1 positive
14
mNSCLC - L1 - TMB>10Mb
1
non squamous cell - mNSCLC - L1
non squamous - mNSCLC - L1 - all population
3
non squamous - mNSCLC - L1 - PDL1 positive
non squamous - mNSCLC - L1 - Wild Type (WT)
6
squamous cell - mNSCLC - L1
squamous - mNSCLC - L1 - all population
4
squamous - mNSCLC - L1 - PDL1 positive
squamous - mNSCLC - L1 - Wild Type (WT)
immune chekpoint inhibitors
anti-CTLA-4
ipilimumab based treatment
ipilimumab plus SoC
anti-PD-(L)1
atezolizumab based treatment
atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus paclitaxel
pembrolizumab based treatment
pembrolizumab plus SoC
versus all
vs chemotherapy
vs non platinum-based chemotherapy
vs taxanes
vs paclitaxel
vs nab-paclitaxel
vs platinum-based chemotherapy
vs platinum derivate
vs platinum association
vs paclitaxel plus carboplatin
vs carboplatin plus nab-paclitaxel
vs Standard of Care (SoC)
vs placebo plus SoC
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
graph
EGM
comparisons
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
ipilimumab plus SoC
title
placebo plus SoC
title
CA184-104, 2017 NCT01285609 squamous - mNSCLC - L1 - all population 479/477
Pathology:
squamous - mNSCLC - L1 - all population;
squamous - mNSCLC - L1 - all population
CA184-104, 2017
ipilimumab plus SoC
1
T1
placebo plus SoC
0
T0